相似文献
1
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Bioorg Med Chem Lett. 2003 Jun 16;13(12):2035-40. doi: 10.1016/s0960-894x(03)00313-5.
2
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
J Med Chem. 2003 May 8;46(10):1811-23. doi: 10.1021/jm020475w.
3
Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Bioorg Med Chem Lett. 2003 Jun 16;13(12):2021-4. doi: 10.1016/s0960-894x(03)00292-0.
4
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
J Med Chem. 2001 Aug 2;44(16):2636-60. doi: 10.1021/jm010127e.
5
Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Bioorg Med Chem Lett. 2001 Nov 19;11(22):2907-10. doi: 10.1016/s0960-894x(01)00603-5.
6
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4293-7. doi: 10.1016/j.bmcl.2003.09.056.
7
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
J Med Chem. 2002 Nov 7;45(23):4954-7. doi: 10.1021/jm0255670.
8
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4299-304. doi: 10.1016/j.bmcl.2003.09.057.
9
Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
Bioorg Med Chem Lett. 2005 Jun 15;15(12):2970-3. doi: 10.1016/j.bmcl.2005.04.039.
10
Reverse hydroxamate-based selective TACE inhibitors.
Bioorg Med Chem Lett. 2004 Jun 7;14(11):2897-900. doi: 10.1016/j.bmcl.2004.03.048.
引用本文的文献
1
Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.
J Comput Aided Mol Des. 2010 Feb;24(2):143-56. doi: 10.1007/s10822-010-9322-z. Epub 2010 Feb 24.
2
A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
J Med Chem. 2005 Apr 7;48(7):2361-70. doi: 10.1021/jm0491703.
Zotero 插件